StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
Allogene Therapeutic
4.94
+0.61%
 

ALLO

 

Allogene Therapeutics

$ 4.94

 
+$0.03 | +0.61%
 
 
Open
$ 4.94
 
 
MKT CAP
$ 831.29M
 
High
$ 5.07
 
 
VOL
$ 1.41M
 
Low
$ 4.88
 
 
AVG VOL
$ 2.42M
 
 
 

ALLO Stock Analysis

  Login to display Allogene Therapeutics (ALLO) recommendation from the last 90 days from financial news and social media.
 
 

ALLO Total Score

 
 
 

Chart

 
 

3.09

2.52

2.98

6.06

 
 
1month
3month
6month
1year
 

ALLO Risk Level

This Indicator assigning ALLO risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
ALLO Risk Level
LOW
HIGH

Risk Volatility

 

ALLO has Low Risk Level

Click here to check what is your level of risk

 

ALLO Analysts Opinion

ALLO overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.00
 

ALLO Earnings Sentiment

 Earnings increase YoY

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

2.00
 

ALLO Momentum Analysis

 Price value has negative momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

NA
 
 
 

ALLO Analysts Opinion

ALLO Analysts opinion is negative and it remained unchanged from the past 3 months

 

ALLO Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
69%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
0%
NA
 
On Track
On Track
On Track
 

ALLO Street Opinion 

ALLO Street view is bullish and have negative views on the near-term outlook

 

ALLO Performance Sentiment

Sentiments overview associated with ALLO events and the stock performance.
 
69%
31%
Positive
Negative
11 out of 16
events present
5 out of 16
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

ALLO Earnings

The TTM reflects 12-month period, providing review of ALLO financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
38
-
 
 
Operating Exp
339
336
294
+7.38%
 
 
Operating Inc
-339
-335
-256
-
 
 
Net Interest Inc
15
5
2
+173.86%
 
 
Interest Exp
-
-
-
-
 
 
Interest Inc
15
5
2
+173.86%
 
 
Other Income
-9
-2
-3
-
 
 
EPS
-2.20
-2.32
-1.89
-
 
 
Next Earnings Date: May 21, 2024
 
 
Highlights
Last Modify
Price
% Change

 
Strong Earnings
2 Month Ago
3.22
+0.31%
 
Cut Workforce
2 Month Ago
2.92
-14.01%
 
 
 
joker
 
 
 
StocksRunner

Explore our ALLO Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our ALLO Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 

Not Enough Information

 
 
 

ALLO Risk Level

 
 
 

The Indicator assigning ALLO risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
ALLO Risk Level
LOW
HIGH

Risk Volatility

 

ALLO has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

ALLO

 

Allogene Therapeutics

$ 4.94

 
+$0.03 | +0.61%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 4.94
 
 
MKT CAP
$ 831.29M
 
High
$ 5.07
 
 
VOL
$ 1.41M
 
Low
$ 4.88
 
 
AVG VOL
$ 2.42M
 
 
 

ALLO Analysis

  Sign in to view Allogene Therapeutics (ALLO) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

3.09

2.52

2.98

6.06

 
 
1month
3month
6month
1year
 

ALLO Analysts Opinion

ALLO Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

4.00
 

ALLO Earnings Sentiment

 Earnings increase YoY

 
 

Rating

×
 

Rating

NA
 
 

Momentum

×
 

Momentum

2.00
 

ALLO Momentum Sentiment

 Price value has negative momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

NA
 
 
 

ALLO Analysts Opinion

ALLO Analysts opinion is negative and it remained unchanged from the past 3 months

 

ALLO Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
69%
Buy
Opinion
Trend
Score
Potential
Score
 
 
NA
0%
NA
 
On Track
On Track
On Track
 

ALLO Street Opinion 

ALLO Street view is bullish and have negative views on the near-term outlook

 
ALLO Performance Sentiment
Sentiments overview associated with ALLO events and the stock performance.
 
69%
31%
Positive
Negative
11 out of 16
events present
5 out of 16
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

ALLO Earnings

The TTM data reflects the most recent 12-month period, providing overview of ALLO financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
38
-
 
 
Operating Exp
339
336
294
+7.38%
 
 
Operating Inc
-339
-335
-256
-
 
 
Net Interest Inc
15
5
2
+173.86%
 
 
Interest Exp
-
-
-
-
 
 
Interest Inc
15
5
2
+173.86%
 
 
Other Income
-9
-2
-3
-
 
 
EPS
-2.20
-2.32
-1.89
-
 
 
Next Earnings Date: May 21, 2024
 
Highlights
Last Modify
Price
% Change

 
Strong Earnings
2 Month Ago
3.22
+0.31%
 
Cut Workforce
2 Month Ago
2.92
-14.01%
 
 
ALLO Latest News Feed

how allogene (allo) stock stands out in a strong industry. one stock that might be an intriguing choice for investors right now is allogene therapeutics inc. allo. this is because this security

Fri Jan 12, 2024

Earnings

allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer. allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer allogene therapeutics is making unexpected changes to development

Fri Jan 5, 2024

Activity

allogene (allo) down 20% on strategic changes in pipeline. shares of allogene therapeutics allo fell 20% in pre-market trading on jan 5 after management announced its business plans for 2024 an

Fri Jan 5, 2024

Momentum

allogene layoffs 2024: what to know about the latest allo job cuts. this biotech stock has seen its downtrend continue today biotechnology company allogene (nasdaq:allo) is certainly not having the day that many in the companys c-suite may have anticipate

Fri Jan 5, 2024

Activity
Momentum

allogene drops on layoffs and pipeline reorganization (update).

Fri Jan 5, 2024

Activity
Momentum

allogene therapeutics to lay off 22% of its workforce. stock down. (rttnews) - gene editing company allogene therapeutics inc. (allo) friday announced its decision to cut down its workforce by 22% in a move to focus on developing its blood cance

Fri Jan 5, 2024

Activity
Momentum

allogene drops on plans for pipeline reorganization.

Fri Jan 5, 2024

Activity
Momentum

allogene to cut 22% of its workforce. gene editing company allogene therapeutics said on friday it will cut 22% of its workforce as part of a clinical development strategy aimed at prioritizing its product pipeline.

Fri Jan 5, 2024

Activity

 
 
 
 
 

Score Tracker

 
 
 
Based on 16 events in the last 90 days from financial news and social media. Last updated Mar 1, 2024 23:12 Wall St. time
 
 

ALLO Total Score

 
 
 
 
 
 
 
StocksRunner

Discover ALLO Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of ALLO. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our ALLO Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

ALLO Stock trends

ALLO Stock performance

ALLO Stock analysis

ALLO investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker